Non-intensive study
CR occurred in 19.6% (The probability of achieving CRMedian (range) follow-up for OS, which included all patients, was 10.0 (0.2–36.1) months in the glasdegib arm and 9.7 (0.3–29.3) months in the placebo arm. OS (unstratified) was similar in both arms (HR 0.99 [95% CI 0.768–1.289]; two-sided 